The Fort Worth Press - US panel weighs authorizing Covid vaccines for youngest children

USD -
AED 3.673025
AFN 68.000474
ALL 93.02026
AMD 388.466711
ANG 1.802136
AOA 913.498985
ARS 1003.990419
AUD 1.535473
AWG 1.8025
AZN 1.703112
BAM 1.859028
BBD 2.018819
BDT 119.494913
BGN 1.865705
BHD 0.376905
BIF 2897.5
BMD 1
BND 1.343751
BOB 6.909335
BRL 5.814602
BSD 0.999857
BTN 84.485602
BWP 13.651378
BYN 3.272548
BYR 19600
BZD 2.015674
CAD 1.397075
CDF 2870.000138
CHF 0.88679
CLF 0.035284
CLP 973.590189
CNY 7.235798
CNH 7.255525
COP 4390.5
CRC 508.292544
CUC 1
CUP 26.5
CVE 105.624964
CZK 24.210407
DJF 177.720346
DKK 7.11744
DOP 60.403608
DZD 133.587786
EGP 49.671971
ERN 15
ETB 123.398836
EUR 0.954275
FJD 2.2963
FKP 0.789317
GBP 0.793955
GEL 2.724982
GGP 0.789317
GHS 15.849983
GIP 0.789317
GMD 71.000041
GNF 8630.000202
GTQ 7.719178
GYD 209.209595
HKD 7.782925
HNL 25.175013
HRK 7.133259
HTG 131.285912
HUF 392.649975
IDR 15921.85
ILS 3.71219
IMP 0.789317
INR 84.486598
IQD 1310.5
IRR 42105.000205
ISK 139.420269
JEP 0.789317
JMD 158.803485
JOD 0.7091
JPY 154.50898
KES 129.498382
KGS 86.491543
KHR 4049.999882
KMF 469.650117
KPW 899.999621
KRW 1400.354986
KWD 0.30764
KYD 0.833321
KZT 495.877273
LAK 21959.999768
LBP 89550.000273
LKR 290.944865
LRD 180.25028
LSL 18.109739
LTL 2.95274
LVL 0.60489
LYD 4.884975
MAD 10.01395
MDL 18.209124
MGA 4670.999775
MKD 58.714642
MMK 3247.960992
MNT 3397.999946
MOP 8.016062
MRU 39.915037
MUR 46.400064
MVR 15.450074
MWK 1735.999934
MXN 20.411085
MYR 4.46498
MZN 63.902276
NAD 18.109792
NGN 1694.17998
NIO 36.790097
NOK 11.065015
NPR 135.177343
NZD 1.705611
OMR 0.38499
PAB 0.999948
PEN 3.795027
PGK 4.026501
PHP 58.980495
PKR 277.912179
PLN 4.144406
PYG 7848.150595
QAR 3.64075
RON 4.748905
RSD 111.645038
RUB 101.299081
RWF 1371
SAR 3.754185
SBD 8.355531
SCR 13.660962
SDG 601.487009
SEK 11.060521
SGD 1.34643
SHP 0.789317
SLE 22.585039
SLL 20969.504736
SOS 571.495264
SRD 35.405036
STD 20697.981008
SVC 8.749543
SYP 2512.529858
SZL 18.120494
THB 34.733968
TJS 10.649728
TMT 3.51
TND 3.153028
TOP 2.342098
TRY 34.477585
TTD 6.787668
TWD 32.550798
TZS 2652.358996
UAH 41.282881
UGX 3694.533288
UYU 42.610626
UZS 12879.999989
VES 46.272339
VND 25422.5
VUV 118.722009
WST 2.791591
XAF 623.500672
XAG 0.032492
XAU 0.000374
XCD 2.70255
XDR 0.762793
XOF 622.000038
XPF 114.249984
YER 249.899323
ZAR 18.10309
ZMK 9001.199618
ZMW 27.574604
ZWL 321.999592
  • RBGPF

    -0.5000

    59.69

    -0.84%

  • CMSD

    0.1850

    24.445

    +0.76%

  • CMSC

    0.1200

    24.64

    +0.49%

  • GSK

    0.3500

    33.7

    +1.04%

  • SCS

    -0.0300

    13.04

    -0.23%

  • RIO

    0.1800

    62.57

    +0.29%

  • NGG

    -0.1700

    63.1

    -0.27%

  • AZN

    1.0600

    64.26

    +1.65%

  • RELX

    0.6500

    45.76

    +1.42%

  • RYCEF

    0.1800

    6.79

    +2.65%

  • BCC

    2.9500

    140.36

    +2.1%

  • BP

    0.4400

    29.52

    +1.49%

  • JRI

    0.0000

    13.23

    0%

  • VOD

    -0.1000

    8.84

    -1.13%

  • BTI

    -0.1000

    36.98

    -0.27%

  • BCE

    -0.3200

    26.68

    -1.2%

US panel weighs authorizing Covid vaccines for youngest children
US panel weighs authorizing Covid vaccines for youngest children / Photo: © AFP/File

US panel weighs authorizing Covid vaccines for youngest children

After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.

Text size:

Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.

Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."

Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.

Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.

They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.

Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.

But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.

There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.

White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.

Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.

Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.

Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.

Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."

H.Carroll--TFWP